VNRX supply chain intelligence for VolitionRx Limited: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LIND | Lindblad Expeditions Holdings, Inc. | 92% | the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Note |
| LIND | Lindblad Expeditions Holdings, Inc. | 92% | Reciprocal relationship from LIND graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from LIND graph: Reciprocal relationship from VNRX graph: the Company must pay Lind an amount… |
| LIND-GLOBAL-ASSET-MANAGEMENT-XII-LLC | LIND-GLOBAL-ASSET-MANAGEMENT-XII-LLC | 92% | VolitionRx Limited issued to Lind Global Asset Management XII LLC certain senior secured convertible promissory notes |
| VSTOCK-TRANSFER-LLC | VSTOCK-TRANSFER-LLC | 92% | In connection with the Offering, the Company also entered into a warrant agent agreement with the Company’s transfer agent, VStock Transfer, LLC |
| HESKA | HESKA | 85% | In exchange for granting Heska exclusive worldwide rights to sell our Nu.Q ® Vet Cancer Test at the point of care for companion animals, Volition received a $10.0 million upfront payment |
| FIRST-INSURANCE-FUNDING | FIRST-INSURANCE-FUNDING | 80% | February 5, 2026, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $ 262,552 |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from ABT grap… |
| ABT | Abbott Laboratories | 72% | ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research… |
| EXAS | Exact Sciences Corp | 72% | Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from EXAS g… |
| EXAS | Exact Sciences Corp | 72% | ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research… |
| MDXH | MDxHealth SA | 72% | Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or c… |
| MDXH | MDxHealth SA | 72% | ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to expand our product development, research… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HESKA | HESKA | 90% | On March 28, 2022, Volition entered into a master license and product supply agreement with Heska, now an Antech Company. | Qwen verified: VolitionRx is the customer as it receives license and produc… |
| ABT | Abbott Laboratories | 72% | ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul… |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from VNRX graph: ies entering the market. The market for diagnostics is also significantly affected by new product introductions and ot… |
| EXAS | Exact Sciences Corp | 72% | Reciprocal relationship from EXAS graph: Reciprocal relationship from VNRX graph: ies entering the market. The market for diagnostics is also significantly affected by new product introductions and o… |
| EXAS | Exact Sciences Corp | 72% | ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul… |
| MDXH | MDxHealth SA | 72% | Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from VNRX graph: Reciprocal relationship from MDXH g… |
| MDXH | MDxHealth SA | 72% | ies entering the market. The market for diagnostics is also significantly affected by new product introductions and other market activities of industry participants. Our competitors include large mul… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VNRX-DEBT-13407 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| VNRX-DEBT-13406 | Warrants outstanding: 0.45 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| VNRX-DEBT | Debt stack $11.5M | 90% | Market cache reports total debt of $11.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VNRX-OWNER-LAGODA-INVESTMENT-MANAGEMENT-L-P | Lagoda Investment Management, L.P. | 90% | 13F overlay lists Lagoda Investment Management, L.P. as top holder; 32 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ABT | Abbott Laboratories | 100.00 | 1 | ['customer', 'supplier'] |
| EXAS | Exact Sciences Corp | 100.00 | 1 | ['customer', 'supplier'] |
| MDXH | MDxHealth SA | 100.00 | 1 | ['customer', 'supplier'] |
| LIND | Lindblad Expeditions Holdings, Inc. | 100.00 | 1 | ['supplier'] |
| HESKA | HESKA | 60.75 | 1 | ['receiving'] |
| WERFEN | WERFEN | 60.75 | 1 | ['receiving'] |
| SVA | Sinovac Biotech Ltd. | 50.00 | 2 | |
| GCTK | GlucoTrack, Inc. | 50.00 | 2 | |
| GRAL | GRAIL, Inc. | 50.00 | 2 | |
| VTAK | Catheter Precision, Inc. | 50.00 | 2 | |
| CODX | Co-Diagnostics, Inc. | 50.00 | 2 | |
| GRFS | Grifols, S.A. | 50.00 | 2 | |
| BSFC | Blue Star Foods Corp. | 50.00 | 2 | |
| DXCM | DexCom, Inc. | 50.00 | 2 | |
| PSNL | Personalis, Inc. | 50.00 | 2 | |
| ENTA | Enanta Pharmaceuticals, Inc. | 50.00 | 2 | |
| GIKLY | Grifols, S.A. | 50.00 | 2 | |
| TECH | Bio-Techne Corporation | 50.00 | 2 | |
| ONCO | Onconetix, Inc. | 50.00 | 2 | |
| FLGT | Fulgent Genetics, Inc. | 50.00 | 2 |